We previously reported on the opening post-trial
briefs in Regeneron's BPCIA case against Mylan and Biocon (who
was added as a defendant after the original defendant, Mylan,
transferred its rights to the aflibercept biosimilar to Biocon).
Now, post-trial briefing is complete.
The parties submitted their responsive briefs on July 24, 2023,
along with proposed findings of fact and conclusions of law. Both
sides' papers were filed under seal. The parties submitted
their reply briefs on July 28, 2023. Defendants' reply brief is
publicly available.
In their 10-page reply brief, Defendants continued to press
their invalidity arguments. Specifically, Defendants argued that
the asserted claims of the dosing patents (the '601 and
'572 patents) are anticipated, obvious, lacking written
description, not enabled, and/or indefinite. Likewise for the
formulation patent (the '865 patent), Defendants argued that
the asserted claims are anticipated, obvious, lacking